drugset / Trial / NCT00889733
Intraperitoneal (IP) Cisplatin Given With Paclitaxel to Treat Epithelial Ovarian Cancer
Phase 1/2
Terminated
9 enrolled
University Health Network, Toronto
Princess Margaret Hospital, Canada · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether intraperitoneal (IP) Cisplatin combined with intravenous (IV) Paclitaxel is well tolerated in women with epithelial ovarian cancer who have had neoadjuvant chemotherapy followed by initial debulking surgery.
Timeline
- Start
- 2007-02
- Primary completion
- 2009-07
- Completion
- 2009-12
Outcome
Outcome not reported
Stopped (Enrollment): “Poor recruitment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | — | Other |
| Subject | Paclitaxel | Small molecule | — | Intravenous |